Pelthos Therapeutics Inc. (PTHS) - Total Assets
Based on the latest financial reports, Pelthos Therapeutics Inc. (PTHS) holds total assets worth $130.40 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore how well can Pelthos Therapeutics Inc. service its debt to assess how comfortably operating cash covers total debt obligations.
Pelthos Therapeutics Inc. - Total Assets Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data. See PTHS net assets for net asset value and shareholders' equity analysis.
Pelthos Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2025)
Pelthos Therapeutics Inc.'s total assets of $130.40 Million consist of 40.4% current assets and 59.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 13.8% |
| Accounts Receivable | $8.86 Million | 6.8% |
| Inventory | $23.57 Million | 18.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $39.47 Million | 30.3% |
| Goodwill | $24.68 Million | 18.9% |
Asset Composition Trend (2021–2025)
This chart illustrates how Pelthos Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see PTHS company net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Pelthos Therapeutics Inc.'s current assets represent 40.4% of total assets in 2025, an increase from 0.0% in 2021.
- Cash Position: Cash and equivalents constituted 13.8% of total assets in 2025, up from 0.0% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 48.0% of total assets, an increase from 0.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 30.3% of total assets.
Pelthos Therapeutics Inc. Competitors by Total Assets
Key competitors of Pelthos Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Ligand Pharmaceuticals Incorporated
NASDAQ:LGND
|
USA | $1.53 Billion |
|
argenx NV ADR
NASDAQ:ARGX
|
USA | $8.68 Billion |
|
Bachem Holding AG
SW:BANB
|
Switzerland | CHF2.11 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Beijing Hotgen Biotech Co Ltd
SHG:688068
|
China | CN¥3.21 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥28.15 Billion |
|
INVENTIVA ADS/1 O.N.
F:6IVA
|
Germany | €249.51 Million |
|
CorMedix Inc
NASDAQ:CRMD
|
USA | $826.14 Million |
Pelthos Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.03 | 0.34 | 0.01 |
| Quick Ratio | 1.12 | 0.34 | 0.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $26.71 Million | $-2.71 Million | $-6.44 Million |
Pelthos Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Pelthos Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.14 |
| Latest Market Cap to Assets Ratio | 0.66 |
| Asset Growth Rate (YoY) | 9424.0% |
| Total Assets | $130.40 Million |
| Market Capitalization | $85.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Pelthos Therapeutics Inc.'s assets below their book value (0.66x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Pelthos Therapeutics Inc.'s assets grew by 9424.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Pelthos Therapeutics Inc. (2021–2025)
The table below shows the annual total assets of Pelthos Therapeutics Inc. from 2021 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $130.40 Million | +9423.99% |
| 2024-12-31 | $1.37 Million | +1320.41% |
| 2023-12-31 | $96.39K | +75.02% |
| 2022-12-31 | $55.07K | -- |
| 2021-12-31 | $0.00 | -- |
About Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 year of age and older; XEPI, (ozenoxacin) cream, a quinolone antimicrobial for the treatment of impetigo due to Staphylococcus aureus or Streptococcus… Read more